News - Research, Merck & Co

Filter

Current filters:

ResearchMerck & Co

Popular Filters

1 to 25 of 78 results

Positive data on Merck & Co’s nausea drug Emend Ph III trial in children

Positive data on Merck & Co’s nausea drug Emend Ph III trial in children

30-06-2014

Positive results have been announced by US pharma giant Merck & Co from a global, investigational Phase…

EmendMerck & CoOncologyPharmaceuticalRegulationResearch

Merck & Co in new accord with Bionomics for CNS research

Merck & Co in new accord with Bionomics for CNS research

24-06-2014

Australian biotech firm Bionomics has entered into a second exclusive research collaboration and license…

BionomicsBiotechnologyBNC375LicensingMerck & CoNeurologicalResearch

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

Excitement as Merck releases new data on cancer drug candidate pembrolizumab

Excitement as Merck releases new data on cancer drug candidate pembrolizumab

03-06-2014

The findings released at the 2014 American Society of Clinical Oncology (ASCO) conference in Chicago…

Merck & CoOncologypembrolizumabPharmaceuticalResearch

Merck and Endocyte pull CMA for vintafolide and companion imaging component in EU

20-05-2014

US pharma giant Merck & Co and Endocyte have withdrawn their conditional marketing authorization applications…

EndocyteEuropeMerck & CoOncologyPharmaceuticalRegulationResearchvintafolide

Merck & Co updates on near-term opportunities and strategy

Merck & Co updates on near-term opportunities and strategy

07-05-2014

US pharma giant Merck & Co, which has just sold its consumer health care business to Bayer for $14.2…

Merck & CoPharmaceuticalRegulationResearch

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

Endocyte plummets on decision to stop vintafolide Ph III trial; posts financials

03-05-2014

US pharma giant Merck & Co and partner Endocyte revealed on Friday that the Data Safety Monitoring Board…

EndocyteFinancialMerck & CoOncologyPharmaceuticalResearchvintafolide

Merck & Co enters deal with Agenus worth a potential $100 million in milestones

Merck & Co enters deal with Agenus worth a potential $100 million in milestones

28-04-2014

USA-based biotech firm Agenus has entered into a collaboration and license agreement with pharma giant…

AgenusBiotechnologyLicensingMerck & CoOncologyResearch

Promising results for Merck & Co’s hepatitis C drug combo

Promising results for Merck & Co’s hepatitis C drug combo

10-04-2014

US pharma giant Merck & Co has announced additional data from the ongoing C-WORTHy study, a multi-arm…

Anti-viralsMerck & CoMK-5172PharmaceuticalResearch

Merck, Ferring and WHO working together to prevent excessive bleeding in women after childbirth

Merck, Ferring and WHO working together to prevent excessive bleeding in women after childbirth

06-04-2014

US pharma giant Merck & Co and privately-held Switzerland-headquartered Ferring Pharmaceuticals have…

carbetocinFerring PharmaceuticalsGlobalMarkets & MarketingMerck & CoPharmaceuticalResearchWomen's Health

Phase II trial shows simvastatin slows progression of multiple sclerosis

21-03-2014

Simvastatin, the active ingredient of Merck & Co’s (NYSE: MRK) now off patent cholesterol-lowerer Zocor,…

Merck & CoNeurologicalPharmaceuticalResearchSimvastatinUK

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

07-03-2014

USA pharma giant Merck & Co subsidiary MSD says that in a 96-week, open-label AIDS Clinical Trials Group…

Anti-viralsIsentressMerck & CoPharmaceuticalResearch

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

05-03-2014

Pharma giant Merck & Co has announced results from a Phase IIb study evaluating two doses of its investigational…

ImmunologicalsMerck & CoPharmaceuticalResearchUSA

High potency statins linked to better outcome following a heart attack

21-02-2014

A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment…

Cardio-vascularezetimibeMerck & CoPharmaceuticalResearchZetia

Joint European program targets novel antibiotic

12-02-2014

More than 30 European universities and companies, led by GlaxoSmithKline and Uppsala University, are…

Antibiotics and Infectious diseasesEuropeMerck & CoPharmaceuticalResearch

Merck and Samsung Bioepis expand collaboration to insulin glargine candidate

Merck and Samsung Bioepis expand collaboration to insulin glargine candidate

11-02-2014

US pharma giant Merck & Co and South Korea’s Samsung Bioepis have expanded their collaboration with…

BiosimilarsDiabetesInsulin Glargine [rDNA origin] InjectionLantusLicensingMerck & CoPharmaceuticalResearchSamsung BioepisSanofi

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

Second research deal with Merck & Co for Ablynx

Second research deal with Merck & Co for Ablynx

03-02-2014

Belgian drugmaker Ablynx has entered into a second research collaboration and licensing agreement with…

AblynxLicensingMerck & CoOncologyPharmaceuticalResearch

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

18-12-2013

US pharma giant Merck & Co says it has initiated a clinical trial to evaluate the combination of the…

GlaxoSmithKlineMerck & CoMK-3475OncologyPazopanib TabletsPharmaceuticalResearch

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

10-12-2013

The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

Strong one-year results in patients with advanced melanoma treated with Merck’s MK-3475

Strong one-year results in patients with advanced melanoma treated with Merck’s MK-3475

19-11-2013

US pharma giant Merck & Co has announced additional data for MK-3475, an investigational anti-PD-1 immunotherapy,…

Merck & CoMK-3475OncologyPharmaceuticalResearch

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

12-11-2013

US pharma giant Merck & Co (NYSE: MRK) has published positive results for its investigational Timothy…

ALK AbelloGrazaxImmunologicalsMerck & CoNorth AmericaPharmaceuticalResearchUSA

1 to 25 of 78 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top